Kodi-M Co Ltd (224060) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kodi-M Co Ltd (224060) has a cash flow conversion efficiency ratio of -1.298x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.54 Billion ≈ $-5.79 Million USD) by net assets (₩6.58 Billion ≈ $4.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 224060 net asset quality index to measure how much of total assets are equity-financed.
Kodi-M Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Kodi-M Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kodi-M Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Kodi-M Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kodi-M Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lunai Bioworks Inc.
NASDAQ:LNAI
|
0.079x |
|
Charn Issara Development Public Company Limited
BK:CI
|
0.112x |
|
FASING SA
WAR:FSG
|
0.009x |
|
StarFlex Co. Ltd
KQ:115570
|
-0.017x |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
-0.243x |
|
Astute Metals NL
AU:ASE
|
-0.011x |
|
Boa Concept SA
PA:ALBOA
|
0.010x |
|
PZ Cormay SA
WAR:CRM
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Kodi-M Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Kodi-M Co Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see 224060 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩10.75 Billion ≈ $7.29 Million |
₩-3.68 Billion ≈ $-2.49 Million |
-0.342x | -190.56% |
| 2024-12-31 | ₩45.19 Billion ≈ $30.63 Million |
₩-5.32 Billion ≈ $-3.60 Million |
-0.118x | +42.92% |
| 2023-12-31 | ₩32.17 Billion ≈ $21.80 Million |
₩-6.63 Billion ≈ $-4.49 Million |
-0.206x | +43.10% |
| 2022-12-31 | ₩46.97 Billion ≈ $31.83 Million |
₩-17.02 Billion ≈ $-11.53 Million |
-0.362x | -86.76% |
| 2021-12-31 | ₩55.69 Billion ≈ $37.74 Million |
₩-10.80 Billion ≈ $-7.32 Million |
-0.194x | +31.34% |
| 2020-12-31 | ₩79.93 Billion ≈ $54.17 Million |
₩-22.59 Billion ≈ $-15.31 Million |
-0.283x | +8.88% |
| 2019-12-31 | ₩65.51 Billion ≈ $44.39 Million |
₩-20.31 Billion ≈ $-13.77 Million |
-0.310x | -1368.33% |
| 2018-12-31 | ₩56.29 Billion ≈ $38.15 Million |
₩1.38 Billion ≈ $932.73K |
0.024x | +288.85% |
| 2017-12-31 | ₩55.27 Billion ≈ $37.45 Million |
₩-715.52 Million ≈ $-484.90K |
-0.013x | +97.41% |
| 2016-12-31 | ₩15.85 Billion ≈ $10.74 Million |
₩-7.91 Billion ≈ $-5.36 Million |
-0.499x | -377.13% |
| 2015-12-31 | ₩12.28 Billion ≈ $8.32 Million |
₩2.21 Billion ≈ $1.50 Million |
0.180x | -- |
About Kodi-M Co Ltd
THE CODI Co.,LTD. manufactures and sells semiconductor and display equipment, exposure equipment, and bio-healthcare products. It develops therapeutic agents for various diseases, such as Zika/MERS, glaucoma, non-alcoholic fatty liver, and chronic kidney diseases, as well as immunotherapy to treat cancer and inflammatory diseases. THE CODI Co.,LTD. was formerly known as CODI-M Co., LTD. and chang… Read more